Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.
Access glioblastoma specialists in Pittsburgh at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioblastoma treatment provided free
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: * Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection * Und
Sponsor: Diakonos Oncology Corporation
Check if you qualify for this glioblastoma clinical trial in Pittsburgh, PA
If you're searching for glioblastoma treatment options in Pittsburgh, PA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.